HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
BIOBOARD - EYE ON CHINA
Hua Medicine's novel glucokinase activator reports positive Phase 1a data for diabetes and initiates Phase 1b trials
Hua Medicine, a leading innovative drug development company in China, has started a multicenter, multi-dose Phase 1b Trials for Diabetes. The company had previously obtained positive results from a Phase 1a trial evaluating HMS5552, a glucokinase activator (GKA) for Type 2 Diabetes, and demonstrated, even at single doses, significant effects in a variety of biochemical diabetes markers such as glucose and glucose-stimulated insulin release (GSIR).

In the Phase 1a study, groups of healthy volunteers were treated with HMS5552 in increasingly higher dose groups. In a dose-dependent manner, HMS5552 consistently increased post-meal GSIR multiple-fold above the post-meal insulin levels seen in the placebo group, with very low risk for hypoglycemia.

"Having abnormally high blood glucose levels after a meal is typical of diabetics and pre-diabetics with impaired glucose tolerance or IGT. Asian patients in particular are at even higher risk for diabetes and IGT compared to Western patients, because of both dietary and genetic factors. In particular, Chinese diabetics suffer from an earlier deterioration in beta cell function. That's why these Phase 1a results showing higher GSIR profiles were important in affirming that HMS5552 should be particularly beneficial in treating Chinese and Asian-dominant diabetics," said Yi Zhang, M.D., Director of Clinical Development at Hua Medicine.

The Phase 1a study of HMS5552 was a blinded, placebo-controlled, dose-escalation study in 60 healthy volunteers. The study was designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and MOA-validation of HMS5552. HMS5552 was evaluated in six single ascending doses ranging from 5mg, 10mg, 15mg, 25mg, 35mg and 50mg, with each dose group having 10 randomized patients (2 placebo, 8 on drug) per group. The trial demonstrated the following.

  • The total adverse events (AE) rate was identical vs. placebo with no relationship between AEs and incidence, types, intensity, or dose of drug. There were no severe AEs, deaths, or premature withdrawals due to AEs, and no significant laboratory, vital signs, or ECG abnormalities

  • Excellent linear correlation between drug dose and plasma exposure, dose-proportional AUC and Cmax across all 6 dose groups, no PK gender differences between male and female subjects, and no major metabolites were seen in plasma at the highest 50mg tested dose group

  • The dose proportional increases in post-meal insulin and GLP-1 levels were notably above placebo post-meal hormone levels, validating GK's pancreatic mechanism of action; dose proportional decreases in fasting glucose without hypoglycemia or significant changes in other regulatory hormones suggesting GK's hepatic MOA via reduction in gluconeogenesis at fasting state.

"In addition to the robust glucose and insulin responses, the substantial increase in post-meal GLP-1 levels demonstrated by HMS5552 at the higher doses was very gratifying to observe. No previous GKA in the clinic had shown significant effects on patient plasma GLP-1 levels, but our pre-clinical models suggested that HMS5552 could indeed increase GLP-1," stated CEO of Hua Medicine, Li Chen. "This effect appears to persist in our Phase 1a trials, and if confirmed in future trials would mark a significant advance in diabetes treatment, since GKA would be affecting most of the major glucose-regulation pathways in the body including insulin secretion, postprandial glucose control, hepatic glucose production, and GLP-1 modulation. We hope this multi-pathway targeting strategy will eventually lead to better, more effective therapies to control disease progression for all patients, but especially the subtype of earlier-stage diabetic patients most predominant in China and Asia."

As a follow-up to these positive Phase 1a trials, the company is now initiating a multicenter Phase 1b trial in diabetic patients that is expected to complete by 3Q-2014. The Phase 1b trial is a randomized, double-blind, placebo-controlled, multiple-ascending dose trial in 50 diabetic adult males and female patients. Daily doses will range from 25 mg to 200 mg (and up to 400 mg if needed) in the trial. In addition to evaluating HMS5552's safety, tolerability, and pharmacokinetics, the trial will evaluate the associated hormone biomarkers and pharmacodynamics of multiple oral doses of HMS5552 over a period of two weeks. These results are expected to further support HMS5552's novel mechanism of action and give guidance for trial design and optimal patient selection in future Phase 2 and Phase 3 trials.

Source: Marketwired News

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy